Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (vol 394, pg 1638, 2019

Bachert C.; Han J. K.; Desrosiers M.

首页> 外文期刊>The Lancet >Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (vol 394, pg 1638, 2019

【24h】

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (vol 394, pg 1638, 2019

机译：Dupilumab在鼻息肉患者严重慢性鼻窦炎患者的疗效和安全性（Liberty NP Sinus-24和Liberty NP sinus-52）：两种多期，随机，双盲，安慰剂控制，并联 - 组3试验结果结果（ Vol 394，PG 1638,2019

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2019年第10209期|共1页
作者
Bachert C.; Han J. K.; Desrosiers M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献

1. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (vol 394, pg 1638, 2019 [J] . Bachert C., Han J. K., Desrosiers M. The Lancet . 2019,第10209期

机译：Dupilumab在鼻息肉患者严重慢性鼻窦炎患者的疗效和安全性（Liberty NP Sinus-24和Liberty NP sinus-52）：两种多期，随机，双盲，安慰剂控制，并联 - 组3试验结果结果（ Vol 394，PG 1638,2019
2. DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COMORBID ASTHMA: SINUS-24/SINUS-52 TRIALS [J] . Gevaert P., Bachert C., Desrosiers M., Annals of allergy, asthma, and immunology . 2019,第5Suppla1期

机译：Dupilumab通过鼻息肉和可鼻疗法和可血管哮喘提高患者报告的患者报告的结果：窦-24 /鼻窦-52试验
3. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma [J] . William W. Busse, Jorge F. Maspero, Klaus F. Rabe, Advances in therapy. . 2018,第5期

机译：自由哮喘任务：第3阶段随机，双盲，安慰剂控制，并行群体研究，评价杜帕里姆采血/安全性，对患者的不受控制，中度至严重的哮喘
4. Liberty Asthma QUEST: Phase 3 Randomized Double-Blind Placebo-Controlled Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled Moderate-to-Severe Asthma [O] . William W. Busse, Jorge F. Maspero, Klaus F. Rabe, -1

机译：自由性哮喘研究：3期随机双盲安慰剂对照平行组研究评估未控制中度至重度哮喘患者的Dupilumab疗效/安全性
5. Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma from the Pooled Populations of the SINUS-24 and SINUS-52 Dupilumab Phase 3 Trials [O] . M. Desrosiers, J. Mullol, K. Forwith, 2020

机译：鼻息肉患者慢性鼻窦炎患者的基线特征，来自窦鼻窦群和鼻窦-52杜氏菌相3试验

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (vol 394, pg 1638, 2019

著录项

相似文献

相关主题

期刊订阅